CTRI/2022/01/039548已完成未知
A Randomized, Double Blind, Placebo Controlled Clinical Study to Evaluate the Efficacy and Safety of Ashwagandha Extract Formulation(ASVAMAN�®) on Improvement of Energy and Endurance in Adults
Manipal Natural Private Limited0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Male healthy adult subjects ranging in age from 18 to 50 years.
- •2. Willingness to follow the protocol requirements as evidenced by written,
- •informed consent.
- •3. Mentally, physically and legally eligible to give informed consent
- •4. Male subjects BMI between 20.0 ââ?¬â?? 25.9 kg/m2
- •5. Willingness to complete study questionnaires.
排除标准
- •1. Patients with pre-existing severe systemic disease necessitating long-term medication.
- •2. Significant medical or psychiatric illness
- •3. History of cancer, including solid tumors, hematologic malignancies and carcinoma in situ
- •4. Any neurological (congenital or acquired), vascular or systemic disorder which could affect any of the efficacy assessments
- •5. Participation in the current or previous treatment with any approved or investigational health supplement(s) during the past 1 month.
- •6. Subjects received other medication (anti-viral) within the 36 hours before entry into the study
- •7. Patients who had immunization against influenza or influenza like illnesses for that season.
- •8. Inability to comply with the study protocol, including psychiatric diseases.
- •9. Immune compromised or with other clinically active illness including cardiac or pulmonary diseases, hemoglobinopathies, renal dysfunction
- •10. Having vaccination of a seasonal or new influenza A (H1N1) vaccine 6 months before.
- •11. Other reasons that researchers think not fitting to participate in the study
- •12. Evidence of significant uncontrolled comorbid disease which in the investigators opinion would jeopardize patient participation.
- •13. Patient tested positive with Covid 19
研究者
相似试验
进行中（未招募）
1 期
A study to evaluate the safety and benefit of Mavacamten (MYK 461) in adults with an inherited heart disease causing thickening of the heart muscleMedDRA version: 20.0Level: PTClassification code 10020871Term: Hypertrophic cardiomyopathySystem Organ Class: 10010331 - Congenital, familial and genetic disordersHypertrophic CardiomyopathyEUCTR2017-002530-23-DKMyoKardia, Inc.220
进行中（未招募）
1 期
A study to evaluate the safety and benefit of Mavacamten (MYK 461) in adults with an inherited heart disease causing thickening of the heart muscleHypertrophic CardiomyopathyEUCTR2017-002530-23-NLMyoKardia, Inc.220
进行中（未招募）
1 期
A study to evaluate the safety and benefit of Mavacamten (MYK 461) in adults with an inherited heart disease causing thickening of the heart muscleHypertrophic CardiomyopathyEUCTR2017-002530-23-GBMyoKardia, Inc.220
进行中（未招募）
1 期
A study to evaluate the safety and benefit of Mavacamten (MYK 461) in adults with an inherited heart disease causing thickening of the heart muscleHypertrophic CardiomyopathyEUCTR2017-002530-23-FRMyoKardia, Inc.220
进行中（未招募）
1 期
A study to evaluate the safety and benefit of Mavacamten (MYK 461) in adults with an inherited heart disease causing thickening of the heart muscleMedDRA version: 20.0Level: PTClassification code 10020871Term: Hypertrophic cardiomyopathySystem Organ Class: 10010331 - Congenital, familial and genetic disordersHypertrophic CardiomyopathyEUCTR2017-002530-23-DEMyoKardia, Inc.220